Investor Overview

Stock Information
Loading data...
Press Releases
Oct 12, 2021

Evofem Biosciences, Inc. (NASDAQ: EVFM) today announced that it has entered into a definitive agreement with Keystone Capital Partners ("Keystone Capital") providing for the issuance and sale of...

Oct 8, 2021

Evofem Biosciences, Inc., (NASDAQ: EVFM) today commented on a letter from leaders in the House of Representatives to senior Biden Administration officials calling for action to ensure coverage for...

Sep 30, 2021

Evofem Biosciences, Inc., (NASDAQ: EVFM) today announced that Chief Executive Officer Saundra Pelletier will present and host one-on-one meetings at the 14th annual LD Micro Main Event being held...

Sep 27, 2021

Evofem Biosciences, Inc., (NASDAQ: EVFM) today announced that a manuscript on the variability of contraceptive clinical trial design and its impact on efficacy outcomes has been published in the...

Sep 16, 2021

Evofem Biosciences, Inc., (NASDAQ: EVFM) today announced that seven data sets from clinical trials of Phexxi® (lactic acid, citric acid and potassium bitartrate) and EVO100 will be presented at...

View all

Evofem Investor Presentation
Subscribe for Alerts

Company Overview

Evofem Biosciences, Inc. (NASDAQ: EVFM) is a commercial-stage biopharmaceutical company committed to developing and commercializing innovative products to address unmet needs in women's sexual and reproductive health. 

The Company‘s first FDA-approved product, Phexxi® (lactic acid, citric acid and potassium bitartrate), is a hormone-free, on-demand prescription contraceptive vaginal gel. It comes in a box of 12 pre-filled applicators and is applied 0-60 minutes before each act of sex. Learn more at  

The Company is evaluating its investigational drug candidate EVO100 for the prevention of chlamydia and gonorrhea in women in a pivotal Phase 3 clinical trial, EVOGUARD. Top-line results are expected in mid-2022 and assuming positive results Evofem plans to file an sNDA in the fourth quarter of 2022.

The addressable U.S. market opportunity for these current and investigational indications is estimated at $3.6 - $4.5 billion in aggregate.  

Evofem intends to expand Phexxi’s global reach and further increase its commercial potential through ex-U.S. licenses. Discussions are underway with potential licensees for commercialization of Phexxi in multiple international markets.

Featured Event
Tuesday, October 12, 2021
03:30 pm EDT

Listen to CEO Saundra Pelletier's presentation at the 14th annual LD Micro Main Event.

View All

Latest Financial Results

Q2 2021, Ended August 11, 2021

Earnings Release
Earnings Call
10-Q Filing